This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At the beginning of September, Velocity Clinical Research topped Business North Carolina ’s 2024 Fast 40 list. For a clinicaltrials organization to achieve this level of scale is notable. Recruitment Clinicaltrial sites live and die by their ability to recruit patients into trials.
Expanding minority Americans’ access to care and clinicaltrials isn’t just the right thing to do. ClinicalTrials Don’t Reflect Demographics. Disease doesn’t discriminate, and researchers understand different populations react differently to drugs. Why, then, are clinicaltrials so stubbornly homogeneous?
Clinicaltrials for pulmonary fibrosis are being conducted to evaluate the effectiveness of novel therapies and interventions, providing hope for improved outcomes in the future. They aim to improve patient outcomes, slow disease progression and enhance quality of life.
Just as clinical researchers in other therapeutic areas have renewed their commitment to improving participant diversity in clinicaltrials, so too have those working in Alzheimer’s research. What Factors Promote Alzheimer’s ClinicalTrial Participation? Similarly, older Latino and Hispanic individuals are 1.5
Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinicaltrials. A 2018 NIH survey found that patients felt clinicaltrial participation to be inconvenient and burdensome, and nearly half (49.0%) said it disrupted their daily routine.
Cardiovascular clinicaltrials need to have a diversity plan because there can be a difference in disease burden when comparing people of different race and ethnicity. The US Food and Drug Administration (FDA) is emphasizing the need for diversity in clinicaltrials. The Diversity of the US Population.
There has been increasing awareness around the need for improving inclusion and diversity in clinicaltrials. As such, there has been a growing emphasis on efforts to achieve better and more accurate representations of minority and underrepresented populations like Black people in clinical studies.
While drugs require Phase I-III clinicaltrials—and are also subject to post-approval tracking—digital therapeutics, devices, and IVDs may be able to leverage bench testing, animal studies, pilot studies, and training sets.
Diverse clinicaltrials are a matter of equity and essential for the validity and reliability of research outcomes. Historically, racial and ethnically minoritized groups or populations have been excluded from clinicaltrials, leading to a lack of data on how different demographic subgroups respond to treatments.
Given the success of Oxford’s Phase II trial, the study investigators are now gearing up for a Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children aged 5 to 36 months across four countries in Africa. Developing an efficacious vaccine against malaria has been a huge challenge.
Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinicaltrial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. Food and Drug Administration (FDA) approval.
(CDS), a leading technology provider focused on data collection and clinicaltrial management, today announced several updates in celebration of its tenth anniversary, including the company’s latest technological development, TrialKit AI, a machine-learning API. About Crucial Data Solutions.
Takeda has forecasted continued financial pressure but is banking on new drugtrials to stabilize its position. Clinical t rial f ailures: Amylyx’s large-scale layoffs underscore the heavy dependence some companies have on a single product.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content